Please ensure Javascript is enabled for purposes of website accessibility

Why RedHill Biopharma Stock Jumped on Tuesday

By Cory Renauer – Aug 31, 2021 at 4:11PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated.

What happened

Shares of RedHill Biopharma (RDHL -27.20%) are on the move after Cantor Fitzgerald initiated coverage of the biopharmaceutical company. Investors excited about the buy rating have pushed the stock 20.3% higher as of 3:15 p.m. EDT on Tuesday.

So what 

RedHill Biopharma has three drugs on the market and six in clinical trials right now. With so much under the hood, it's no wonder analysts think it's a bargain at its ultralow valuation. Yesterday this company had a market cap of around $360 million.

Investor looking at an upward sloping chart on their computer.

Image source: Getty Images.

Early last year the company began marketing Talicia for the treatment of Helicobacter pylori infections in adults. Roughly one-third of people get an H. pylori infection at some point in their life. While they usually clear up without lingering issues, these infections can cause peptic ulcers and increase the risk of stomach cancer.

The company is also developing opaganib, a novel sphingosine kinase inhibitor, as a potential stomach cancer treatment. Opaganib is in a phase 2 oncology trial at the moment, plus enrollment in a phase 2/3 study has been completed for its use in treatment of COVID-19. 

Now what

Sales of RedHill's commercial-stage drugs aren't exactly amazing. Despite it being in the middle of multiple new drug launches, top-line revenue during the second quarter came in at a measly $21.5 million, which was only about $600,000 more than the company reported in the previous-year period.

Multibillion-dollar valuations aren't uncommon for companies that have zero commercial-stage products, so it's not hard to see why Cantor Fitzgerald thinks this stock is undervalued. The important thing for individual investors to understand is that the stock only appears undervalued on a risk-adjusted basis. While eventual approval of its clinical-stage drugs could propel the stock many times higher, there's still a lot that could go wrong and result in irrecoverable losses.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Redhill Biopharma Stock Quote
Redhill Biopharma
RDHL
$0.27 (-27.20%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.